Literature DB >> 21725985

Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.

H K Crewe1, Z E Barter, K Rowland Yeo, A Rostami-Hodjegan.   

Abstract

The 'relative activity factor' (RAF) compares the activity per unit of microsomal protein in recombinantly expressed cytochrome P450 enzymes (rhCYP) and human liver without separating the potential sources of variation (i.e. abundance of enzyme per mg of protein or variation of activity per unit enzyme). The dimensionless 'inter-system extrapolation factor' (ISEF) dissects differences in activity from those in CYP abundance. Detailed protocols for the determination of this scalar, which is used in population in vitro-in vivo extrapolation (IVIVE), are currently lacking. The present study determined an ISEF for CYP2C9 and, for the first time, systematically evaluated the effects of probe substrate, cytochrome b5 and methods for assessing the intrinsic clearance (CL(int) ). Values of ISEF for S-warfarin, tolbutamide and diclofenac were 0.75 ± 0.18, 0.57 ± 0.07 and 0.37 ± 0.07, respectively, using CL(int) values derived from the kinetic values V(max) and K(m) of metabolite formation in rhCYP2C9 + reductase + b5 BD Supersomes™. The ISEF values obtained using rhCYP2C9 + reductase BD Supersomes™ were more variable, with values of 7.16 ± 1.25, 0.89 ± 0.52 and 0.50 ± 0.05 for S-warfarin, tolbutamide and diclofenac, respectively. Although the ISEF values obtained from rhCYP2C9 + reductase + b5 for the three probe substrates were statistically different (p < 0.001), the use of the mean value of 0.54 resulted in predicted oral clearance values for all three substrates within 1.4 fold of the observed literature values. For consistency in the relative activity across substrates, use of a b5 expressing recombinant system, with the intrinsic clearance calculated from full kinetic data is recommended for generation of the CYP2C9 ISEF. Furthermore, as ISEFs have been found to be sensitive to differences in accessory proteins, rhCYP system specific ISEFs are recommended.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725985     DOI: 10.1002/bdd.760

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  12 in total

1.  Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.

Authors:  Ling Song; Yi Zhang; Ji Jiang; Shuang Ren; Li Chen; Dongyang Liu; Xijing Chen; Pei Hu
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

2.  Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.

Authors:  Rachel H Rose; David B Turner; Sibylle Neuhoff; Masoud Jamei
Journal:  AAPS J       Date:  2017-05-19       Impact factor: 4.009

3.  Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Pieter Colin; Jan Van Bocxlaer; Pieter Annaert; Filip Cuyckens; An Vermeulen; Achiel Van Peer; Karel Allegaert; Geert Mannens; Koen Boussery
Journal:  Pharm Res       Date:  2014-07-22       Impact factor: 4.200

4.  Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.

Authors:  Yongjie Zhang; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Clin Pharmacol       Date:  2016-11-16       Impact factor: 4.335

5.  In vitro-in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans.

Authors:  Miaoying Shi; Yumeng Dong; Hans Bouwmeester; Ivonne M C M Rietjens; Marije Strikwold
Journal:  Arch Toxicol       Date:  2022-05-23       Impact factor: 6.168

6.  Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.

Authors:  Yuan Lu; Jinbo Yang; Haiyan Zhang; Jin Yang
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

7.  A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.

Authors:  Colin J Henderson; Lesley A McLaughlin; Robert D Finn; Sebastien Ronseaux; Yury Kapelyukh; C Roland Wolf
Journal:  Drug Metab Dispos       Date:  2013-10-10       Impact factor: 3.922

8.  Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.

Authors:  Marco Siccardi; Adeniyi Olagunju; Kay Seden; Farid Ebrahimjee; Steve Rannard; David Back; Andrew Owen
Journal:  In Silico Pharmacol       Date:  2013-03-01

9.  Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.

Authors:  Marco Siccardi; Phillip Martin; Darren Smith; Paul Curley; Tom McDonald; Marco Giardiello; Neill Liptrott; Steve Rannard; Andrew Owen
Journal:  J Interdiscip Nanomed       Date:  2016-09-29

10.  Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children.

Authors:  X-L Jiang; P Zhao; J S Barrett; L J Lesko; S Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.